Oklahoma Senate Bill SB1563

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Nonopioid drugs; modifying certain restrictions on Medicaid drug formulary; prohibiting certain carriers from imposing specified utilization controls. Effective date.

Summary

SB1563 would change Oklahoma law to give nonopioid pain medications more favorable treatment in both the state Medicaid program and certain state employee health coverage arrangements. For Medicaid, the bill amends existing law to require the Oklahoma Health Care Authority and any contracted entity to avoid imposing more restrictive prior authorization, step therapy, or other utilization controls on FDA-approved nonopioid pain drugs than the least restrictive controls applied to comparable opioid or narcotic pain drugs. It also bars the Authority from denying coverage of an approved nonopioid pain drug in favor of an opioid drug when prescribed by a contracted provider. The bill also creates a new section allowing a carrier offering a state employee flexible benefit plan to adopt or amend a state preferred drug list (PDL). If a nonopioid pain drug is covered, the carrier may not place it under more restrictive utilization controls than the least restrictive controls applied to opioid or narcotic pain drugs approved for pain treatment. The bill defines “nonopioid drug” for this purpose and applies the rule to drugs already approved for coverage or provided under pharmacy benefit manager contracts. The act would take effect January 1, 2027.

Impact

SB1563 would amend Title 63 Medicaid formulary rules and add a new Title 74 provision governing state employee flexible benefit plans and preferred drug lists. Its practical effect is to limit how much managed care entities, pharmacy benefit managers, and state plan carriers can restrict access to FDA-approved nonopioid pain medications, especially by preventing stricter prior authorization or step therapy requirements than those used for opioid alternatives. It would not ban opioid coverage or preference among opioids, but it would require parity or better treatment for qualifying nonopioid pain drugs in the specified state programs.

Sentiment

The available legislative record shows the bill was introduced and referred to the Health and Human Services committee, but no committee transcript or vote history is provided. Based on the bill’s structure and caption, the measure appears to be framed as a patient-access and opioid-alternative policy, suggesting a generally supportive policy intent around expanding access to nonopioid pain treatment. Because there are no recorded debates or votes in the provided materials, there is no direct evidence of opposition or support beyond the bill text itself.

Contention

The main policy tension in SB1563 is between expanding access to nonopioid pain medications and preserving utilization management tools used by Medicaid programs, carriers, and pharmacy benefit managers to control costs and prescribing. The bill specifically limits prior authorization and step therapy for nonopioid pain drugs, which could be viewed as reducing administrative barriers for patients, but also as constraining formulary management. Another possible point of contention is the bill’s parity approach: it does not eliminate utilization controls, but requires nonopioid pain drugs to be treated no more restrictively than opioid or narcotic pain drugs, which may raise concerns among payers about formulary flexibility and cost containment.